Observational Study on Venetoclax Use in Chronic Lymphocytic Leukemia Patients Receiving Real-Life Treatments Across Austria, Germany, and Switzerland
Led by AbbVie · Updated on 2026-10-21
500
Participants Needed
74
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines.
Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies.
During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.
CONDITIONS
Brief Title
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Research Team
J
Johannes Huelsenbeck
S
Stefan Lorenz
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy as specified in the local label for any treatment line
You will not qualify if you...
None
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Observation Period
Duration - Up to 12 months
Participants receive venetoclax alone or in combination with other treatments as prescribed by their physician. Researchers collect data on treatment response, health costs, and patient-reported outcomes during regular care.
Regular visits as per routine care
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Similar Trials
Safety and Effectiveness Study of GT801 Injection in Adults With Relapsed or Refractory CD19-positive B-cell Blood Cancers and Autoimmune Hemolytic Anemia
Phase 1 Open-Label Study of UB-VV111 With and Without Rapamycin in Relapsed or Refractory CD19 B-Cell Malignancies
Phase 12 Study of IDP-121 Treatment in Adults With Relapsed or Resistant Blood Cancers Including Multiple Myeloma and Lymphomas
Phase 2 Study of BGB-16673 Combined with Sonrotoclax for Untreated Chronic Lymphocytic Leukemia CLL
Phase 1 Study Evaluating Safety and Treatment Effects of Oral NX-2127 in Adults with Relapsed or Resistant B-cell Cancers
Evaluation of Oral NX-5948 in Adults with RelapsedRefractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL-2 Inhibitors
Phase 1 Study Evaluating Oral NX-5948 Safety and Activity in Adults with Relapsed or Refractory B-cell Cancers
Long-Term Safety Study of Lisocabtagene Maraleucel Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in a Post-Marketing Setting
Phase III Study of IL-7IL-15 Expanded CAR-2019-T Cells for Adults With Relapsed or Refractory B-Cell Malignancies Including NHL, CLL, and CNS Lymphoma
Study of Hairy Cell Leukemia and Other Cancers Focusing on Recombinant Immunotoxin Research and Sample Collection
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.